Interventions to Reduce Surgical Site Infection in Transmetatarsal Forefoot Amputations: A Feasibility Survey (2026)

Type of publication:

Journal article

Author(s):

*Alawattegama, Lakna Harindi; Al-Saadi, Nina; Bosanquet, David; Chetter, Ian; Fabre, Ismay; Garnham, Andrew; Gwilym, Brenig; Hitchman, Louise; Long, Judith; Magill, Laura; Worrallo, Katie; Pinkney, Thomas; Popplewell, Matthew; Wall, Michael.

Citation:

International Wound Journal. 23(4):e70846, 2026 Apr.

Abstract:

Surgical site infection (SSI) following transmetatarsal amputation (TMA) is common and associated with significant morbidity. However, there is limited evidence to guide perioperative strategies for SSI prevention in this population. A prospective, cross-sectional survey was conducted among vascular specialists. The questionnaire assessed current practice in SSI prevention for TMA, perceptions of evidence gaps, and willingness to participate in future research. Responses were analysed descriptively. Eighty-four valid responses were analysed, with 64.3% from consultant vascular surgeons and 84.5% from UK centres. Most respondents (84.5%) considered SSI after TMA to be a significant issue. The majority preferred primary closure in clean wounds (78.6%) and commonly used short-course antibiotics and interrupted sutures. Over 70% agreed no clear best practice exists, and 65.5% felt high-quality randomised trials are needed. Ninety-three percent expressed willingness to engage in future studies. Equipoise existed regarding interventions including antibiotic duration, wound adjuncts, and closure techniques. Opinion varied regarding whether TMA and major lower limb amputation should be pooled when undertaking research into SSI prevention. Current practice in SSI prevention for TMA is highly variable. This survey demonstrates broad support for rigorous trials to establish effective strategies and highlights the feasibility of future research in this area.

DOI: 10.1111/iwj.70846

Link to full-text [open access - no password required]

Continuous Infusion and Sequential Nephron Blockade Versus Bolus Furosemide in Acute Heart Failure: A Systematic Review (2026)

Type of publication:

Systematic review

Author(s):

Ahmed Mohamed, Leena Awad Alkareem; *Abozaid, Khalid; Mohammed Ahmed Hassan, Hala Fakhri; Ali, Yasir; Hussein Abdalla, Nibras Elfatih; Ibrahim, Mohamed Samir Yasin; Ahmed Mohammed, Weam Mohammed; Babikir Omer, Ahmed Mohammed; Awad, Alaa.

Citation:

Cureus. 18(6):e111063, 2026 Jun.

Abstract:

Acute heart failure (AHF) is a leading cause of hospitalization worldwide, with congestion as its central pathophysiologic feature. Loop diuretics, particularly furosemide, remain the cornerstone of decongestive therapy, yet the optimal administration strategy, continuous infusion versus bolus dosing, remains debated. Furthermore, sequential nephron blockade through the addition of distal tubule-acting diuretics or sodium-glucose cotransporter-2 (SGLT2) inhibitors has emerged as a strategy to overcome diuretic resistance. This systematic review had two primary objectives: first, to compare continuous infusion versus bolus dosing of furosemide; second, to evaluate the efficacy and safety of adjunctive sequential nephron blockade (SGLT2 inhibitors, thiazides, and acetazolamide) added to loop diuretics within the context of the ongoing debate over optimal decongestion in AHF. A systematic literature search was conducted in PubMed, Scopus, Web of Science, the Cochrane Library, and ClinicalTrials.gov for studies published between 2021 and 2025. Eligible studies included randomized controlled trials (RCTs) and prospective observational studies evaluating either continuous furosemide infusion versus bolus furosemide or adjunctive sequential nephron blockade (added to loop diuretics) versus placebo, usual care, or, in one case, an active diuretic comparator. The Cochrane Risk of Bias 2 (RoB 2) tool was used for RCTs, and the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) tool was used for the nonrandomized study. A narrative synthesis was performed because of substantial clinical and methodological heterogeneity. Ten studies (nine RCTs and one prospective observational study) comprising 2,972 patients were included. Continuous furosemide infusion consistently improved surrogate measures of decongestion (urine output and weight loss) compared with bolus dosing. However, these benefits did not reliably translate into improved symptoms or shorter hospital stays, and one large study reported increased renal injury and adverse events, highlighting a potential efficacy-safety trade-off. Sequential nephron blockade with SGLT2 inhibitors enhanced diuresis with favorable renal and electrolyte safety profiles and a nonsignificant trend toward lower mortality (the studies were not powered for mortality). Thiazide-based strategies achieved potent diuresis but significantly increased the risks of acute kidney injury and electrolyte disturbances without a mortality benefit. Acetazolamide improved decongestion safely but did not reduce mortality or readmissions. No single decongestive strategy is universally superior. However, direct comparisons across strategies are limited by substantial heterogeneity in study design, patient populations (e.g., renal function and congestion severity), and outcome definitions. Continuous furosemide infusion offers enhanced diuresis but inconsistent clinical benefits and potential renal harm. Based largely on surrogate outcomes from heterogeneous studies not designed to detect differences in mortality or readmissions, definitive clinical recommendations remain limited. SGLT2 inhibitors represent a promising but not yet proven adjunct in AHF, pending larger, adequately powered trials. Thiazide-based sequential blockade should be reserved for refractory cases with close monitoring. Treatment should be individualized based on baseline renal function, congestion severity, and electrolyte status.

DOI: 10.7759/cureus.111063

Link to full-text [open access - no password required]

Fecal Microbiota Transplantation (FMT) in the Management of Ulcerative Colitis: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs) (2026)

Type of publication:

Systematic review

Author(s):

Ahad, Amal; Kumar, Sandeep; Kolomar, Hugh; Williams, Jada; Abdallah, Abrar I; Sadeghzadegan, Amirali; *Yateem, Dana; Kharel, Punam; Chowdhury, Dristy; Alnajar, Fahad; Ali, Muqaddas.

Citation:

Cureus. 18(6):e111804, 2026 Jun.

Abstract:

Ulcerative colitis (UC) is a chronic inflammatory disorder of the colon with increasing global prevalence, particularly in newly industrialized countries. Fecal microbiota transplantation (FMT) has worked as an effective therapeutic strategy aimed at restoring immune homeostasis and gut microbial balance. However, a lack of standardized protocols and comprehensive safety data necessitates further evaluation. This meta-analysis aims to comprehensively analyze the efficacy of FMT in inducing clinical remission in UC, incorporating the latest randomized controlled trials (RCTs). A systematic review and meta-analysis of RCTs investigating FMT in UC were conducted. The primary outcomes were clinical and endoscopic remission, while adverse events (AEs) were assessed as secondary outcomes. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated, and heterogeneity was analyzed using the I2 statistic and Cochran's Q test. Overall, FMT demonstrated a significant benefit in inducing clinical remission compared with placebo (RR 1.55; 95% CI 1.22-1.96; p = 0.0003). For endoscopic remission, FMT showed a significant overall effect (RR 1.68; 95% CI 1.15-2.46; p = 0.007). The incidence of AEs was comparable between the FMT and control groups (RR 0.88; 95% CI 0.77-1.00; p = 0.06). This meta-analysis gives strong confirmation for the efficacy of FMT in inducing both clinical and endoscopic remission in UC patients, with a favorable safety profile. Multi-donor FMT and oral capsule administration appear to be particularly promising. Future research should focus on standardizing protocols, elucidating mechanisms of action, and conducting larger, long-term trials to optimize FMT for UC.

DOI: 10.7759/cureus.111804

Link to full-text [open access - no password required]

Coexistence of Elevated Mean Platelet Volume and Bleeding Symptoms in Chronic Kidney Disease: A Discordant Hemostatic Profile (2026)

Type of publication:

Journal article

Author(s):

Adeyeye, Ayomide; Abdul Sattar, Tehzeeb; Mani Tripathi, Kaushalendra; Ali, Sahil; Samuel, Paul Sunday; Uzzaman, Gkm Rashik; *Oso, Ayodeji; Abughazal, Mahmoud Am; Shreen, Sibgha

Citation:

Cureus. 18(6):e111383, 2026 Jun.

Abstract:

BACKGROUND: Hemostasis in chronic kidney disease (CKD) is currently becoming a complicated and disturbed process, not a simple bleeding disorder. Recent evidence suggests that the combination of elevated mean platelet volume (MPV) and bleeding, particularly during the initial phases of the disease, is a discordant hemostatic profile.

OBJECTIVE: To examine the association between mean platelet volume (MPV) and bleeding symptoms among patients with chronic kidney disease (CKD) and to evaluate the utility of platelet indices in characterizing a discordant hemostatic profile.

METHODS: This analytical cross-sectional study recruited 527 patients with CKD from tertiary care centers. Bleeding was measured on a questionnaire that included typical bleeding symptoms and a bleeding score. Platelet indices, such as mean platelet volume (MPV), platelet distribution width (PDW), and platelet count, were provided in the medical records. Data were evaluated using nonparametric tests, logistic regression, and receiver operating characteristic (ROC) curves.

RESULTS: Bleeding symptoms were observed in 298 patients (56.5%). Bleeding participants had increased MPV, which increased with increasing CKD stages. Multivariate analysis showed MPV was significantly associated with bleeding symptoms (OR = 2.88, p < 0.001). ROC curves indicated moderate discriminative ability (area under the curve (AUC) = 0.730), but poor performance of PDW and non-predictive value of platelet count.

CONCLUSION: CKD is associated with a discordant hemostatic profile of elevated MPV alongside bleeding symptoms. MPV may serve as a potential marker associated with bleeding symptoms in patients with CKD.

DOI: 10.7759/cureus.111383

Link to full-text [open access - no password required]

Trochanteric Buttress Plate Augmentation of the Proximal Femoral Nail for Unstable Intertrochanteric Fractures: A Randomized Controlled Trial (2026)

Type of publication:

Randomised controlled trial

Author(s):

*Abdelaty Shalaby, Mohamed H; *Khafagy, Doaa G; Hosny, Mohamed M; Eltantawy, Ahmed E; Omran, Ali M.

Citation:

Cureus. 18(2):e104235, 2026 Feb.

Abstract:

BACKGROUND: Unstable intertrochanteric (IT) fractures pose a significant challenge in orthopedic surgery.

OBJECTIVE: To investigate the effectiveness of combining a trochanteric buttress plate (TBP) with a proximal femoral nail (PFN) for managing unstable IT fractures.

METHODS: This randomized controlled open-label study was performed on 90 patients with recent unstable IT fractures (Evans types 1c, 1d, 1e, or 2). Patients were randomly divided into two groups: Group A was treated with standard PFN fixation. Group B was treated with PFN integrated with TBP augmentation. Assessments were conducted at two weeks and monthly for six months. Functional outcomes were assessed using the modified Harris Hip Score (mHHS).

RESULTS: Operative time and blood loss were significantly higher in Group B (PFN+TBP) than in Group A (standard PFN) (P = 0.005 and 0.006, respectively). Postoperative mHHS was significantly higher in Group B at all follow-up intervals from two weeks to six months (P < 0.05).

CONCLUSIONS: The integration of the TBP with PFN for unstable IT fractures significantly improves functional outcomes without increasing major complications, despite a modest increase in operative time and blood loss.

DOI: 10.7759/cureus.104235

Link to full-text [open access - no password required]

Point-of-care echocardiography training pathways: a global perspective and the need for standardisation (2026)

Type of publication:

Journal article

Author(s):

Abbawy, Marcus, Holden, Finlay, Fisher, Tom, Nasa, Prashant, Manjunathasawamy, Akshay Hiryur, Renukappa, Suresh, Suresh, Subashini, Kumar, Nanda, Ingram, Tom, Hothi, Sandeep, Cotton, James M, *Maharaj, Aruna, Chacko, Cyril, Veenith, Tonny

Citation:

Open Heart. 13(1), 2026 May 26.

Abstract:

Point-of-care ultrasound echocardiography has become an indispensable tool for rapid clinical assessment in emergency medicine. This review article examines the heterogeneity in training pathways globally, outlining the advantages and presenting the challenges to standardisation, documentation practices and quality assurance. By reviewing current curricula, training methods and international models, we aim to identify the positive elements and propose a framework for an ideal national training programme, including the potential role of an examination and higher education institutions.

DOI: 10.1136/openhrt-2026-004057

Link to full-text [open access - no password required]

Artificial Intelligence and Digital Therapy for Adolescent Mental Health in the UK; Opportunities, Barriers, and Ethical Consideration (2025)

Type of publication:

Journal article

Author(s):

Adindu K.N.; Akubue N.; Jude N.O.; Onakoya A.; Chukwunonye C.; Odion O.; *Okengwu C.G.; Uchechukwu N.; Osita-Obasi P.Z.; Ezike A.; Bello I.; Olenloa E.; Eruteya O.O.; Oyewole S.A.

Citation:

SSRN. (no pagination), 2025. Date of Publication: 20 May 2025.

Abstract:

Background: Adolescence constitutes a critical developmental stage marked by the onset of mental health difficulties, yet timely access to effective mental health care remains a significant challenge for many adolescents in the United Kingdom (UK). Artificial intelligence (AI)-enabled digital therapies present innovative opportunities to address these gaps. Objective(s): This systematic review critically assesses current evidence on AI-driven digital interventions for adolescent mental health within the UK, highlighting their potential opportunities, barriers to implementation, and pertinent ethical considerations. Method(s): Employing a mixed-methods design, a systematic literature review adhering to PRISMA guidelines was combined with thematic analysis of semi-structured interviews. Comprehensive database searches (MEDLINE, PsycINFO, Web of Science; 2013-2023) targeted studies involving UK adolescents (ages 11-19) using AI-based mental health technologies. Included studies underwent rigorous quality appraisal (Cochrane RoB 2.0, ROBINS-I, CASP). Additional insights were gathered through stakeholder interviews (clinicians, AI developers, adolescent users). Result(s): Twenty-seven studies met inclusion criteria, investigating interventions such as AI chatbots, predictive analytics, mobile apps, and virtual environments targeting anxiety and depression. Key opportunities identified include enhanced accessibility for underserved populations, personalization through adaptive algorithms, proactive early-risk detection, scalability, cost-efficiency, and improved engagement via interactive interfaces. Significant implementation barriers encompassed technical infrastructure limitations, data security concerns, insufficient longitudinal efficacy data, socioeconomic disparities, and clinician scepticism. Ethical challenges emphasized informed consent, algorithm transparency, potential biases, unclear accountability, and clinician deskilling risks. Conclusion(s): AI-driven digital interventions offer substantial promise for augmenting adolescent mental health services in the UK. However, realizing their full potential necessitates addressing infrastructural, ethical, and evidentiary challenges through robust governance frameworks and continued rigorous research.

DOI: 10.2139/ssrn.5253224

Link to full-text [open access - no password required]

Carbapenem-resistant Enterobacterales across the UK: A nationwide study of carbapenemase testing and novel antimicrobial activity (2026)

Type of publication:

Journal article

Author(s):

Baltas I.; Drury K.; Harrison T.; Moore N.; Lester R.; Chattaway M.A.; England B.; Cattrall J.W.S.; Donaldson C.J.; Jamal Khan D.P.; Carroll A.; Ball D.; Wareham D.W.; Pahalage R.; Banavathi K.; Drazho B.; Shorrocks R.E.; Hlaing W.; Adhikaree N.; Ryan F.; Thompson J.V.; Connolly G.; Shibu P.; Ale E.; Mirfenderesky M.; Jain S.; Fowler S.; Beard K.; Hughes G.; Bonnici G.; Mohammed T.; Brown K.; Drazich-Taylor S.; Martinez A.S.; Lipworth S.; Crawford-Jones D.; Elnour M.; Moore J.; Democratis J.; McCormick J.; Hussain A.; Islam J.; Jenkins D.; Stoesser N.; Hopkins K.; Demirjian A.; Hatcher J.; Soares A.L.; Kirby A.; Grandjean L.; Riley U.; Stephens J.; Joseph A.; Winzor G.; Jackson K.E.; Kandil H.; Barker B.; Planche T.; Jawad S.; Merrick B.; Snell L.B.; Subbaraj K.P.; Munthali P.G.; Clayton J.J.; Varghese R.; Jones C.R.; Hardman N.L.; Komosa M.M.; Heppell B.M.; Halstead F.D.; Qaiser S.; Mavrogiorgou E.; Nye C.; Bamber S.; Locke T.E.; Whatmore J.; Mohamed F.; Adobah E.; Knox K.; Campbell O.; Carson A.A.; North P.; Albur M.; Tickell-Painter M.; Mooney H.; Coward A.; Shah A.; Choudhury R.Y.; Sughayer H.M.; Graham C.; Mutch C.P.; Dewar S.; Hesing S.C.; Khan S.; Garcia-Mingo A.; Garcia D.M.; Penciu F.; Kosaraju K.; Davey E.; Vazquez A.M.; Qazzafi Z.; *Anand M.; Navalan H.; Roberts S.; Mermerelis D.; Read A.; Rangaiah J.; Austin-Hutchison R.; Price J.R.; Peters J.; Stevens M.; Knapper F.; Merchant N.; Davies F.; Vanstone G.L.; Allen D.; Prior-ong M.; Tuharska Z.; Soper I.; Tsui R.; Watts A.; Kakkar N.; Patel M.; Townsley H.; Saajan P.; Claxton A.P.; Burns P.J.; Jeppesen C.A.; Lee M.; Tudor A.; Macnaughton E.; McKeating C.; Dhillon R.; Okoliegbe I.; Sakka N.E.; Scott K.S.; Wang D.B.; Wilson B.; Laing-Herridge K.; Diver-Hall E.

Citation:

International Journal of Antimicrobial Agents. 67(10) (no pagination), 2026. Article Number: 107898. Date of Publication: 01 Oct 2026. [epub ahead of print]

Abstract:

Background Carbapenem-resistant Enterobacterales (CRE) are increasing in the UK, but the drivers of this rise and effective treatment options remain uncertain. Methods Ninety-seven acute National Health Service Trusts, including 192 UK hospitals, submitted data on 8840 consecutive, non-duplicate CRE (October 2023 to September 2024) and local laboratory methods. Results Predominant CRE species were Klebsiella pneumoniae (30.6%, 2709/8840), Escherichia coli (29.3%, 2592/8840), Enterobacter cloacae complex (22.2%, 1966/8840). Overall, 21.8% (1927/8840) of CRE were collected in outpatient settings. Overall, 85.5% (7279/8513) of CRE underwent carbapenemase detection testing, with significant variation depending on species, specimen type, and baseline antibiogram. Carbapenemases detected were OXA-48-like (22.3%, 1967/8840), NDM (18.6%, 1645/8840), KPC (9.2%, 817/8840), IMP (2.0%, 178/8840), VIM (0.7%, 62/8840), multi-carbapenemase producers (4.0%, 351/8840). Overall, 51.2% (4526/8840) of CRE were tested against >=1 novel agent. In-house antimicrobial susceptibility testing availability was common for ceftazidime-avibactam (90.7%, 88/97) and cefiderocol (73.2%, 71/97), while less common for meropenem-vaborbactam (41.2%, 40/97), imipenem-relebactam (21.6%, 21/97), aztreonam-avibactam (11.3%, 11/97). OXA-48-like- (97.6%, 1138/1166) and KPC producers (96.2%, 429/446) remained susceptible to ceftazidime-avibactam; KPC producers to meropenem-vaborbactam (99.4%, 160/161) and imipenem-relebactam (98.4%, 62/63). Cefiderocol resistance was 32.4% overall and higher among NDM- (58.4%) and multi-carbapenemase producers (50.3%). Ceftazidime-avibactam plus aztreonam synergy was performed for 17.2% (286/1658) of aztreonam-resistant metallo-beta-lactamase-producers; synergy was observed in 78.7% (225/286) of cases. Colistin resistance was 10.6% (153/1445) among non-intrinsically resistant species. Conclusions Whilst most UK CRE are tested for carbapenemases, coverage gaps persist. The community burden of CRE is increasing. Cefiderocol resistance is concerningly high, particularly among metallo-beta-lactamase-producers.

DOI: 10.1016/j.ijantimicag.2026.107898

Link to full-text [open access - no password required]

Understanding the Nuanced Concept of Hemodynamic Incoherence and Its Underlying Physiology (2026)

Type of publication:

Journal article

Author(s):

Rola P.; *Miller A.; Haycock K.; Spiegel R.; Rikhraj K.; Kattan E.; Hernandez G.

Citation:

Journal of Clinical Medicine. 15(15) (no pagination), 2026. Article Number: 5811. Date of Publication: 01 Aug 2026. [epub ahead of print]

Abstract:

Hemodynamic incoherence is commonly defined as a dissociation between normalization of macrocirculatory variables and persistent impairment of tissue perfusion. However, this phenomenon is not physiologically homogeneous. We propose a conceptual distinction between two forms of macro-microcirculatory incoherence. Type 1 incoherence represents primary microcirculatory dysfunction, in which intrinsic alterations in microvascular regulation and flow distribution lead to heterogeneous capillary perfusion despite apparently adequate upstream hemodynamics, as observed in sepsis. In contrast, Type 2 incoherence reflects secondary impairment of microcirculatory flow resulting from hemodynamic constraints elsewhere in the circulation, including excessive vasoconstriction, limited cardiac forward flow, or venous congestion. In this setting, impaired perfusion arises from ineffective transmission of flow across the system rather than primary microvascular failure. The four-interface model of the circulation provides a unifying physiological framework to interpret these mechanisms as failures of energy transfer across sequential hemodynamic domains. Recognizing these distinct forms of incoherence may improve not only physiologic interpretation of shock and help avoid conflating fundamentally different mechanisms under a single conceptual entity, but also be key in individualizing therapeutic interventions to the proper phenotypes of tissue malperfusion

DOI: 10.3390/jcm15155811

Link to full-text [open access - no password required]

Variation in antenatal anaemia guidelines across the NHS in the United Kingdom: A cross-sectional study (2026)

Type of publication:

Journal article

Author(s):

Haynes S.; Balboula I.; Collins P.; *Parry-Smith W.; Fye H.; *Elsmore A.; Collis R.; De Lloyd L.; Churchill D.; Bell S.F.; Stanworth S.J.

Citation:

British Journal of Haematology. (no pagination), 2026. Date of Publication: 2026. [epub ahead of print]

Abstract:

Antenatal anaemia affects up to 30% of pregnant women in the United Kingdom and is a recognised clinical priority. National management guidance is published by the British Society of Haematology (BSH), but the extent to which local National Health Service (NHS) guidelines align with it is unknown. We conducted a cross-sectional document analysis of antenatal anaemia guidelines from 49 NHS sites across the United Kingdom, obtained through two national research programmes. Two reviewers independently extracted data on screening, diagnosis, treatment and monitoring, using the 2020 BSH guideline as the national reference standard. The included guidelines represented approximately 33% of annual UK births. Screening and diagnostic haemoglobin thresholds were broadly consistent with BSH guidance, whereas substantial variation was concentrated in treatment and monitoring: oral iron indications, dosing and duration; haemoglobin thresholds and clinical criteria for intravenous iron; and the timing, biomarkers and response definitions used after treatment. Ferritin thresholds, reassessment intervals and response criteria were frequently absent or divergent. Variation was greatest in domains where the underlying evidence base is least resolved. These findings characterise the nature and extent of guideline-level variation across NHS maternity care and identify priority areas for future research and national guideline development.

DOI: 10.1111/bjh.70780

Link to full-text [open access - no password required]